Dan-Arin Silasi MD

Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences; Director, 'Discovery to Cure' International Fellowship Program in Gynecologic Oncology; Director, Obesity Robotic Pelvic Surgery Program

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Women's Reproductive Cancers Program | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., University of Medicine and Pharmacy of Timisoara, Romania (1993)
  • Resident, University of Texas Health Science Center , Obstetrics/Gynecology (2001 - 2005)
  • Resident, New York University Harbor Healthcare System , Internal Medicine (1999 - 2001)
  • Fellow, Yale University School of Medicine , Gynecologic Oncology

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Gynecologic cancers (ovarian, uterine, cervical, vulvar, and vaginal cancers); Gestational trophoblastic neoplasia; Complicated laparoscopic surgery; Robotic surgery; Single-port laparoscopic surgery; Advanced and complicated pelvic surgery; Chemotherapy for gynecologic cancers


Cancers Treated

Cervix, Gestational Trophoblastic Neoplasia, Ovary, Uterus, Vagina & Vulva


Board Certifications

  • Gynecologic Oncology, Board Certified (2012)
  • Obstetrics & Gynecology, Board Certified (2010)

Clinical Trials

ConditionsStudy Title
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors

Edit Profile